Cascade Pharmaceuticals Inc, a Sino-foreign joint venture biomedical enterprise, held a signing ceremony on March 2 to mark its move to  the Lingang Life Science & Tech Park – located in the Lin-gang Special Area, in East China's Shanghai.

Founded in 2017, Cascade focuses on innovative drugs that target nuclear receptors and G protein coupled receptors, or GPCRs.

Its team is said to have accumulated more than 20 years of innovative drug research and development in the fields of metabolic diseases, tumors and inflammation targeting nuclear receptors – with the company saying that they lead the way in structure-based drug designs.

By entering the Lingang Life Science & Tech Park, Cascade will promote original drug R&D and it aims to achieve new breakthroughs in the field of nuclear hormone receptors and in the R&D of G-protein coupled receptor drugs.

Cascade holds a ceremony to mark its move to the Lingang Life Science & Tech Park. [Photo/WeChat ID: shlgguanweihui]